Allogene Therapeutics
Hayung Y. has extensive experience in the field of scientific research, currently serving as a Scientist at Allogene Therapeutics since May 2018. Prior to this role, Hayung Y. contributed as a Scientist at Pfizer from December 2008 to April 2018 and worked as a Staff Research Associate at UC Davis between June 2000 and December 2008. Research expertise includes skeletal muscle atrophy and hypertrophy, focusing on various animal models, as well as thyroid hormone receptor studies and HIV vaccine development. Hayung Y. possesses a strong proficiency in techniques such as genomic DNA extraction, mRNA isolation, PCR, Western blotting, and immunohistochemistry. Educational background includes a Bachelor of Arts in Biological Sciences and Political Science from the University of California, Davis, completed in 2000.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.